Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | FYN | P06241 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517881 | 0.90 | TNF (0.63) | TNFPIK3CAKCNH2FYNPIK3CD | |
| SCHEMBL3517855 | 0.84 | TNF (0.60) | TNFPIK3CAKCNH2FYNPIK3CD | |
| SCHEMBL3513020 | 0.81 | TNF (0.65) | TNFPIK3CAKCNH2FYNPIK3CD | |
| SCHEMBL3518090 | 0.80 | TNF (0.72) | TNFPIK3CAKCNH2FYNPIK3CD | |
| SCHEMBL3517851 | 0.80 | TNF (0.63) | TNFPIK3CAKCNH2FYNPIK3CD | |
| SCHEMBL3512871 | 0.79 | TNF (0.68) | TNFPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3515795 | 0.79 | TNF (0.50) | TNFPIK3CAFYNPIK3CDPIK3CB | |
| SCHEMBL3516049 | 0.79 | TNF (0.62) | TNFPIK3CAKCNH2FYNPIK3CD | |
| SCHEMBL3515935 | 0.78 | TNF (0.52) | TNFPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3513053 | 0.77 | TNF (0.62) | TNFPIK3CAKCNH2FYNPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | TNF 1981/4885PIK3CA 10/4885KCNH2 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.